Lonza Reports Strong H1 2026 Results and Upgrades Outlook

Lonza Group AG has reported a strong performance in the first half of 2026, with sales reaching CHF 3.4 billion, driven by a 16% growth in constant exchange rates (CER). The company's CORE EBITDA margin improved significantly, rising by 4.4 percentage points to 34.8%, resulting in a CORE EBITDA of CHF 1.2 billion. This was achieved through strong operational execution and strategic growth projects.

Free Cash Flow also improved, reaching CHF 0.4 billion. The company experienced sustained demand across technologies and geographies, including an expansion of its collaboration with a major US biopharmaceutical company. Lonza announced expanding its aseptic ADC drug product capacity in Stein, backed by a long-term customer commitment.

The company has upgraded its full-year CORE EBITDA margin outlook to 33-34%, with an unchanged CER sales growth forecast of 11-12%. Lonza continues to focus on its core as a contract development and manufacturing organization (CDMO).